Licence / Approval / Cancellation

Regulatory approvals continued to drive activity across the pharmaceutical and industrial sectors. Several companies secured key clearances, including Gland Pharma receiving USFDA approval and a successful launch for its Sugammadex Injection, while Alembic Pharmaceuticals gained USFDA approval for Prucalopride Tablets and AstraZeneca India received an additional indication approval for Enhertu in India. In the industrial space, OMDC Belkundi Mine received environmental clearance, and Rhetan TMT secured BIS certification for its TMT bars, opening access to government infrastructure projects. Notably, the RBI excluded Coöperatieve Rabobank U.A. from its Second Schedule, signaling a shift in its banking status, while PFC’s subsidiary incorporated a new SPV for a transmission project. These developments highlight ongoing efforts to strengthen domestic manufacturing capabilities and improve access to essential medicines and infrastructure.